A groundbreaking wearable mini-pump designed for heart failure treatment could revolutionize patient care by enabling earlier hospital discharge and home treatment. Developed by researchers at the University of Glasgow, this device delivers furosemide, a diuretic medication, subcutaneously. The findings from the SUBCUT HF II clinical trial, presented at the European Society of Cardiology Heart Failure Congress 2026 in Barcelona, revealed that patients using the pump were discharged nearly five days earlier than those receiving traditional intravenous treatment. This innovation is particularly relevant for India, where cardiovascular diseases account for nearly 28% of all deaths, and hospital admissions for heart failure are increasing. The mini-pump allows patients to manage their condition at home after initial hospital stabilization, significantly improving their quality of life while reducing the burden on healthcare systems. Experts emphasize the need for careful patient selection and training for effective home-based care. As healthcare systems globally grapple with rising chronic diseases, this wearable technology may represent a significant shift toward decentralized cardiac care.